Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Cancer Prevention
•
Breast Cancer, Non-metastatic
•
Primary Care
How do you counsel patients about hormonal contraception in patients with high risk benign breast pathology (i.e. LCIS, ADH, ALH) who would quality for chemoprevention?
Related Questions
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
What is your preferred method of surveillance after mastectomy?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
Do you follow LFTs in patients on tamoxifen as suggested in the prescribing guidelines?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
What adjuvant therapy would you recommend for a premenopausal woman with low ER+/PR+ (1-10%) HER2- pT1cN0 metaplastic breast cancer?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Is there data to support the substitution of docetaxel with nab-paclitaxel in the TCHP neoadjuvant regimen in the event of hypersensitivity?
